McCann: Cahill to lead global practice

Share this article:
John Cahill, previously president of McCann Healthcare EMEA and Asia-Pacific as well as medical education, becomes worldwide CEO of the network. The previous CEO, Richard Nordstrom, left the company at the end of 2009 and was replaced by an “Office of the CEO” leadership team consisting of: Cahill; Marci Piasecki, CEO of Torre Lazur Healthcare Group; Maureen Regan, managing partner of RCW Group; and David Bachmann, worldwide CFO.

He will report to Nick Brien, CEO of McCann Worldgroup. Brien, who took the reins at McCann in April, wanted an individual to lead healthcare. “We thank the team that has been collaborating in the ‘Office of the CEO' and are pleased that John will now be the single accountable leader for this incredibly important company,” said Brien in a statement, calling the healthcare business “one of our most important growth assets.”

Cahill got his start in healthcare as a researcher working in immunology before working in sales and marketing for Revlon's Technicon and Merck Sharpe and Dohme. He was a founding partner of CWFS Advertising, a top healthcare agency in Australia and New Zealand that was acquired by McCann in 1996. That year, he moved to China to build the company's healthcare practice there. He was named Asia-Pacific director for healthcare in 1998 and regional director EMEA in 2009.

He'll be advised by a global leadership team including Regan, Piasecki and Bachmann as well as Charlie Buckwell, CEO of medical communications, Jeremy Perrott, global executive creative director for healthcare, Amar Urhekar, EVP Japan and Asia-Pacific, and Mark Worman, EVP Europe.

RCW Group boasts a staff of around 220 and clients including Novartis and BMS. Torre Lazur has around 170 employees servicing clients including Boehringer Ingelheim, GSK and Novartis.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?